Akari Historical Balance Sheet

AKTX Stock

USD 0.87 0.03 3.33%

Trend analysis of Akari Therapeutics PLC balance sheet accounts such as Total Assets of 4.8 M, Other Current Liabilities of 5.7 M or Total Current Liabilities of 7.9 M provides information on Akari Therapeutics' total assets, liabilities, and equity, which is the actual value of Akari Therapeutics PLC to its prevalent stockholders. By breaking down trends over time using Akari Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Akari Therapeutics PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Akari Therapeutics PLC is a good buy for the upcoming year.

Akari Therapeutics Inventory

(2.13 Million)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akari Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About Akari Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Akari Therapeutics PLC at a specified time, usually calculated after every quarter, six months, or one year. Akari Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Akari Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Akari currently owns. An asset can also be divided into two categories, current and non-current.

Akari Therapeutics Balance Sheet Chart

At this time, Akari Therapeutics' Other Current Liabilities is fairly stable compared to the past year. Total Current Liabilities is likely to rise to about 7.9 M in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 4.7 M in 2025.

Common Stock Shares Outstanding Total Assets Other Current Liab Total Current Liabilities

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Akari Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Akari Therapeutics PLC books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Akari Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Akari Therapeutics PLC are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Akari Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Akari Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akari Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	11.1M	2.9M	3.3M	5.7M
Total Assets	13.8M	4.4M	5.0M	4.8M

Other Current Liab Total Assets

Akari Therapeutics balance sheet Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Non Current Assets Total	Property Plant And Equipment Gross	Short Term Debt	Current Deferred Revenue	Short Long Term Debt	Intangible Assets	Other Liab	Net Tangible Assets
Common Stock Shares Outstanding		0.71	0.65	0.65	0.7	-0.69	-0.18	0.43	0.68	0.71	0.83	0.61	-0.35	0.21	0.63	0.7	0.62	-0.46	0.9	0.04	-0.46	-0.55	-0.55	0.79	0.28	0.59
Total Assets	0.71		0.85	0.88	0.99	-0.99	0.09	0.73	0.99	1.0	0.4	0.6	-0.23	0.08	0.88	1.0	0.59	-0.41	0.86	-0.15	-0.41	-0.45	-0.44	0.83	0.08	0.93
Other Current Liab	0.65	0.85		0.99	0.78	-0.86	-0.22	0.57	0.86	0.85	0.34	0.49	-0.22	0.31	0.99	0.85	0.5	-0.42	0.68	0.09	-0.42	-0.53	-0.51	0.8	0.13	0.79
Total Current Liabilities	0.65	0.88	0.99		0.81	-0.89	-0.2	0.69	0.89	0.88	0.31	0.47	-0.17	0.3	1.0	0.88	0.48	-0.39	0.69	0.09	-0.39	-0.52	-0.5	0.83	0.13	0.84
Total Stockholder Equity	0.7	0.99	0.78	0.81		-0.97	0.16	0.72	0.97	0.99	0.42	0.6	-0.23	0.01	0.81	0.99	0.59	-0.41	0.88	-0.19	-0.41	-0.42	-0.4	0.8	0.09	0.92
Net Debt	-0.69	-0.99	-0.86	-0.89	-0.97		-0.1	-0.73	-1.0	-0.99	-0.34	-0.56	0.25	-0.06	-0.89	-0.99	-0.56	0.39	-0.85	0.15	0.39	0.43	0.41	-0.81	-0.02	-0.91
Retained Earnings	-0.18	0.09	-0.22	-0.2	0.16	-0.1		-0.08	0.11	0.12	-0.27	0.07	-0.51	-0.94	-0.18	0.09	0.05	0.59	0.15	-0.86	0.59	0.68	0.69	-0.32	-0.13	0.12
Accounts Payable	0.43	0.73	0.57	0.69	0.72	-0.73	-0.08		0.73	0.71	0.12	0.24	0.13	0.21	0.67	0.73	0.24	-0.2	0.5	0.14	-0.2	-0.37	-0.37	0.7	0.11	0.75
Cash	0.68	0.99	0.86	0.89	0.97	-1.0	0.11	0.73		0.99	0.33	0.56	-0.25	0.05	0.89	0.99	0.56	-0.38	0.85	-0.16	-0.38	-0.42	-0.4	0.8	0.0	0.91
Cash And Short Term Investments	0.71	1.0	0.85	0.88	0.99	-0.99	0.12	0.71	0.99		0.38	0.57	-0.27	0.04	0.88	1.0	0.57	-0.38	0.87	-0.17	-0.38	-0.42	-0.4	0.8	0.08	0.93
Net Receivables	0.83	0.4	0.34	0.31	0.42	-0.34	-0.27	0.12	0.33	0.38		0.66	-0.13	0.3	0.3	0.4	0.66	-0.44	0.71	0.03	-0.44	-0.53	-0.53	0.65	0.18	0.22
Common Stock Total Equity	0.61	0.6	0.49	0.47	0.6	-0.56	0.07	0.24	0.56	0.57	0.66		-0.35	-0.02	0.5	0.6	1.0	-0.32	0.74	-0.45	-0.32	-0.4	-0.39	0.72	-0.08	0.37
Non Current Liabilities Total	-0.35	-0.23	-0.22	-0.17	-0.23	0.25	-0.51	0.13	-0.25	-0.27	-0.13	-0.35		0.6	-0.19	-0.23	-0.35	-0.23	-0.41	0.57	-0.23	-0.23	-0.22	-0.01	-0.17	-0.23
Other Stockholder Equity	0.21	0.08	0.31	0.3	0.01	-0.06	-0.94	0.21	0.05	0.04	0.3	-0.02	0.6		0.28	0.08	0.0	-0.64	-0.04	0.82	-0.64	-0.72	-0.75	0.4	0.04	0.02
Total Liab	0.63	0.88	0.99	1.0	0.81	-0.89	-0.18	0.67	0.89	0.88	0.3	0.5	-0.19	0.28		0.88	0.5	-0.38	0.69	0.06	-0.38	-0.5	-0.48	0.83	0.13	0.83
Total Current Assets	0.7	1.0	0.85	0.88	0.99	-0.99	0.09	0.73	0.99	1.0	0.4	0.6	-0.23	0.08	0.88		0.59	-0.41	0.86	-0.15	-0.41	-0.45	-0.43	0.83	0.08	0.93
Common Stock	0.62	0.59	0.5	0.48	0.59	-0.56	0.05	0.24	0.56	0.57	0.66	1.0	-0.35	0.0	0.5	0.59		-0.34	0.73	-0.42	-0.34	-0.42	-0.4	0.73	-0.06	0.37
Short Long Term Debt Total	-0.46	-0.41	-0.42	-0.39	-0.41	0.39	0.59	-0.2	-0.38	-0.38	-0.44	-0.32	-0.23	-0.64	-0.38	-0.41	-0.34		-0.35	-0.53	1.0	0.83	0.83	-0.59	-0.13	-0.26
Non Current Assets Total	0.9	0.86	0.68	0.69	0.88	-0.85	0.15	0.5	0.85	0.87	0.71	0.74	-0.41	-0.04	0.69	0.86	0.73	-0.35		-0.29	-0.35	-0.44	-0.42	0.79	0.08	0.72
Property Plant And Equipment Gross	0.04	-0.15	0.09	0.09	-0.19	0.15	-0.86	0.14	-0.16	-0.17	0.03	-0.45	0.57	0.82	0.06	-0.15	-0.42	-0.53	-0.29		-0.53	-0.51	-0.53	0.12	0.32	-0.06
Short Term Debt	-0.46	-0.41	-0.42	-0.39	-0.41	0.39	0.59	-0.2	-0.38	-0.38	-0.44	-0.32	-0.23	-0.64	-0.38	-0.41	-0.34	1.0	-0.35	-0.53		0.83	0.83	-0.59	-0.13	-0.26
Current Deferred Revenue	-0.55	-0.45	-0.53	-0.52	-0.42	0.43	0.68	-0.37	-0.42	-0.42	-0.53	-0.4	-0.23	-0.72	-0.5	-0.45	-0.42	0.83	-0.44	-0.51	0.83		0.99	-0.71	-0.1	-0.33
Short Long Term Debt	-0.55	-0.44	-0.51	-0.5	-0.4	0.41	0.69	-0.37	-0.4	-0.4	-0.53	-0.39	-0.22	-0.75	-0.48	-0.43	-0.4	0.83	-0.42	-0.53	0.83	0.99		-0.69	-0.14	-0.31
Intangible Assets	0.79	0.83	0.8	0.83	0.8	-0.81	-0.32	0.7	0.8	0.8	0.65	0.72	-0.01	0.4	0.83	0.83	0.73	-0.59	0.79	0.12	-0.59	-0.71	-0.69		0.15	0.69
Other Liab	0.28	0.08	0.13	0.13	0.09	-0.02	-0.13	0.11	0.0	0.08	0.18	-0.08	-0.17	0.04	0.13	0.08	-0.06	-0.13	0.08	0.32	-0.13	-0.1	-0.14	0.15		0.24
Net Tangible Assets	0.59	0.93	0.79	0.84	0.92	-0.91	0.12	0.75	0.91	0.93	0.22	0.37	-0.23	0.02	0.83	0.93	0.37	-0.26	0.72	-0.06	-0.26	-0.33	-0.31	0.69	0.24

Click cells to compare fundamentals

Akari Therapeutics Account Relationship Matchups

Akari Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Common Stock Shares Outstanding	1.6M	2.1M	3.1M	4.9M	5.6M	4.7M
Total Assets	17.6M	11.6M	13.8M	4.4M	5.0M	4.8M
Other Current Liab	1.8M	4.3M	11.1M	2.9M	3.3M	5.7M
Total Current Liabilities	5.2M	6.1M	12.0M	4.6M	5.3M	7.9M
Total Stockholder Equity	12.4M	5.6M	1.8M	(229K)	(206.1K)	(195.8K)
Net Debt	(14.1M)	(9.4M)	(13.2M)	(3.8M)	(4.4M)	(4.6M)
Retained Earnings	(156.6M)	(199.7M)	(217.5M)	(227.5M)	(204.7M)	(194.5M)
Accounts Payable	3.4M	1.8M	947K	1.7M	1.9M	2.1M
Cash	14.1M	9.4M	13.2M	3.8M	3.5M	3.3M
Cash And Short Term Investments	14.1M	9.4M	13.2M	3.8M	3.5M	3.3M
Liabilities And Stockholders Equity	17.6M	11.6M	13.8M	4.4M	5.0M	4.8M
Non Current Liabilities Total	1.0M	3.4M	4.3M	946.7K	1.1M	1.1M
Other Stockholder Equity	191.9M	205.3M	219.3M	174.8M	201.0M	117.1M
Total Liab	5.2M	6.1M	12.0M	4.6M	5.3M	8.1M
Total Current Assets	17.6M	11.6M	13.8M	4.3M	5.0M	4.7M
Accumulated Other Comprehensive Income	(10.9M)	(541.0K)	(770.8K)	51.2M	58.8M	61.8M
Common Stock	385K	476.0K	744.5K	1.3M	1.5M	1.4M
Non Current Assets Total	27K	22.9K	16.9K	14K	12.6K	12.0K
Property Plant And Equipment Gross	20.4K	5.0K	172K	164.9K	197.8K	207.7K
Intangible Assets	27K	22.9K	16.9K	14K	16.1K	28.1K
Net Tangible Assets	3.1M	(1.8M)	9.4M	5.5M	5.0M	4.7M
Other Current Assets	521.9K	2.3M	564.8K	496K	570.4K	954.4K
Net Invested Capital	(1.8M)	9.4M	5.6M	1.8M	1.6M	1.5M
Net Working Capital	(1.8M)	9.4M	5.5M	1.8M	1.6M	1.5M
Capital Stock	32.0M	384.7K	476.0K	744.5K	670.0K	636.5K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Akari Stock Analysis

When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Akari Historical Balance Sheet

Akari Therapeutics Inventory

(2.13 Million)

About Akari Balance Sheet Analysis

Akari Therapeutics Balance Sheet Chart

Common Stock Shares Outstanding

Total Assets

Total Current Liabilities

Akari Therapeutics balance sheet Correlations

Akari Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Akari Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for Akari Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Short Term Debt	+ 1.0	Short Long Term Debt Total

Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.99	Total Assets
Net Debt	- 0.97	Total Stockholder Equity
Other Stockholder Equity	- 0.94	Retained Earnings